Li L, Mi Y, Xu M, Ruan L, Sun J, Song Q
There was no significant change in CMAP negative peak amplitude or area measurements between treatment groups after 6 months (Table 5)
10.2174/138945011798184155 Curr
The evolving treatment landscape includes a diverse array of therapeutic options, such as H3 histamine receptor inverse agonists/antagonists (WAKIX [pitolisant]), therapies targeting extra-oral bitter taste receptors (TAS2R) (ARD-101), PDE-10 inhibitors (PBF-999), triple monoamine reuptake inhibitors (CSTI-500), melanocortin-4 receptor agonists (Setmelanotide), among others
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a tripeptide naturally present in human blood plasma at concentrations averaging 200 ng/mL at age 20, declining to approximately 80 ng/mL by age 60